B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $7 from $9 and keeps a Buy rating on the shares. The Q3 earnings update included a development plan revision for the registration-enabling Phase III VERSATILE-003 trial in HPV16-positive head and neck squamous cell carcinoma, with a sample size reduction from about 440 to roughly 350 patients while maintaining statistical power on the overall survival primary efficacy endpoint, the analyst tells investors in a research note. Management also acknowledged the potential impact of recent FDA approval of Keytruda in adjuvant and neoadjuvant HNSCC to be factored in this development plan revision, including via a recently commissioned survey of more than 50 oncologists treating HNSCC patients, the firm adds.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotechnology Highlights Clinical Progress and Q3 Results
- PDS Biotechnology price target lowered to $4.50 from $7 at Alliance Global Partners
- PDS Biotechnology reports Q3 EPS (29c), consensus (28c)
- PDSB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- PDS Biotechnology presents rationale, design for study evaluating PDS01ADC